Quarterly pharmacy formulary change notice

Similar documents
Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Step Therapy Requirements. Effective: 11/01/2018

Step Therapy Requirements. Effective: 05/01/2018

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

Quarterly pharmacy formulary change

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS

Step Therapy Requirements. Effective: 1/1/2019

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

ANTICONVULSANTS. Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

Quarterly pharmacy formulary change notice

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

Quarterly pharmacy formulary change notice

FirstCarolinaCare Insurance Company. Step Therapy Requirements

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

ANTICONVULSANTS. Details

Step Therapy Requirements

Quarterly pharmacy formulary change notice

ANTICONVULSANTS. Details

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

ANTICONVULSANTS. Details

Opioid Management Program May 2018

Opioid Management Program October 2018

Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)

5-ASA. Products Affected DIPENTUM 250 MG CAPSULE LIALDA 1.2 GRAM TABLET,DELAYED RELEASE. Details

5-ASA. Products Affected. Details. Dipentum 250 mg capsule. Lialda 1.2 gram tablet,delayed release

Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

Pequot Health Care Opioid Analgesic Quantity Program*

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

Step Therapy Medications

Quarterly pharmacy formulary change notice

UPDATE Ohana QUEST Integration Medicaid

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

FirstCarolinaCare Insurance Company Step Therapy Requirements

Upper Peninsula Health Plan Advantage (HMO) (List of Covered Drugs)

Step Therapy Requirements. Effective: 12/01/2016

5-ASA. Products Affected Dipentum 250 mg capsule. Details. Lialda 1.2 gram tablet,delayed release

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE

Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria

Rationale for Decision Excluded Generic OTC equivalent available (Flonase Allergy Relief) Medicare status (if differs)

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir

Step Therapy Requirements

Step Therapy Requirements. Effective: 03/01/2015

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives

Quarterly Pharmacy Formulary Change Notice

PDP Classic Formulary Addendum

ALLERGIC CONJUNCTIVITIS AGENTS

ANGIOTENSIN RECEPTOR BLOCKERS

Quarterly pharmacy formulary change

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

ARBS MEDICATION(S) SUBJECT TO STEP THERAPY DIOVAN HCT MG TAB, DIOVAN HCT MG TABLET

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives

STEP THERAPY ALGORITHMS PUP Select Formulary

WellCare s South Carolina Preferred Drug List Update

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

Quarterly pharmacy formulary change notice

JANUVIA 50 MG TABLET BYDUREON 2 MG/0.65 ML JARDIANCE 10 MG TABLET SUBCUTANEOUS PEN INJECTOR JARDIANCE 25 MG TABLET BYDUREON BCISE 2 MG/0.

Health Partners Medicare Prime 2019 Formulary Changes

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives

Aetna Better Health of Illinois Medicaid Formulary Updates

Step Therapy Requirements

Table 1: Price increases for Brand Name Drugs with Generic Equivalents

Provider update: Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice

Emblem Medicaid 3Q18 Formulary Updates

UPDATE WellCare s South Carolina

Oral Agents. Fml Limits. Available Strengths NF NF

HEALTH SHARE/PROVIDENCE (OHP)

IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MAY 29, 2012

Opioid Analgesic/Opioid Combination Products

Step Therapy Criteria 2019

Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions

Quarterly pharmacy formulary change notice

Simply Step Therapy Document September 2018 Y0114_18_33074_I_009

MEDICAID PROVIDER BULLETIN December 2017 Quarterly pharmacy formulary change notice. Effective for all patients on February 1, 2018

Step Therapy Approval Criteria

Transcription:

https://providers.amerigroup.com Quarterly pharmacy formulary change notice Summary: The formulary changes listed in the table below were reviewed and approved at our fourth-quarter Pharmacy and Therapeutics Committee meeting. Effective May 1, 2018, the changes outlined below apply to all Amerigroup Community Care patients. Effective for all patients on May 1, 2018 Therapeutic class Drug Revised status INHALED CORTICOSTEROIDS FLOVENT HFA INHALER FLOVENT DISKUS FOR ALL AGES EFFECTIVE 4/15/18 Potential alternatives INHALED CORTICOSTEROIDS AEROSPAN 80 MCG INHALER NON PROTON PUMP INHIBITORS PROTON PUMP INHIBITORS ZEGERID 20 MG OTC ACID REDUCER DR 20 MG CAP OMEPRAZOLE DR 20 MG CAPSULE FOR MEMBERS < 6 YEARS OF AGE ANTICOAGULANTS XARELTO COVERED ANTICOAGULANTS SAVAYSA COVERED MISC ANTINEOPLASTIC KADCYLA ADD PA BULK CHEMICALS CALCIUM CARBONATE POWDER NON COUGH AND COLD PREPARATIONS COUGH AND COLD PREPARATIONS GLP-1 RECEPTOR AGONIST HEPATITIS C HYPERAMMONEMIA MULTISYMPTOM COLD LIQUID (OTC) MULTISYMPTOM COLD CAPLET/SOFTGEL COLD & ALLERGY ELIXIR (OTC) HYDROXYZINE 50 MG/25 ML SYRUP CYPROHEPTADINE 4 MG/10 ML SYRP OTC GENERIC 12-HR DECONGEST 120 MG CAPLET OZEMPIC SOVALDI SODIUM PHENYLBUTYRATE POWDER SODIUM PHENYLBUTYRATE 500 MG TB NON WITH ST AND QL 0.25 MG DOSE; 1 PEN/28 S 1 MG DOSE; 2 PENS/28 S EFFECTIVE 4/01/18 NON WITH PA WITH PA EPCLUSA ZEPATIER PA REQUIRED GAPEC-2382-18 April 2018

IRON REPLACEMENT IRON REPLACEMENT MISCELLANEOUS ANTIASTHMATICS ICAR 15 MG/1.25 ML SUSPENSION VENOFER 200 MG/10 ML VIAL VENOFER 100 MG/5 ML VIAL FERROUS FUMARATE 29 MG TAB PARVLEX TABLET FERRO-SEQUELS 65-25 MG CAPLET DIALYVITE 800 WITH IRON TAB IRONUP 15 MG/0.5 ML DROPS FERROUS SULFATE ER 140 MG TAB DEXFERRUM 50 MG/ML VIAL DEXFERRUM 100 MG/2 ML VIAL FERRIC X-150 CAPSULE DUOFER 28 MG TABLET FOCALGIN DSS TABLET CHEWABLE IRON 30 MG TABLET THEOCHRON ER 100 MG TABLET ACETYLCYSTEINE 10% VIAL NON MISCELLANEOUS ANTIASTHMATICS XOLAIR 150 MG VIAL WITH PA NUTRITIONAL SUPPLEMENT VP-ZEL TABLET NON OMEGA-3 FATTY ACIDS FISH OIL OTC FISH OIL SOFTGEL NON POTASSIUM REPLACEMENT POTASSIUM CL ER 8 MEQ CAPSULE POTASSIUM CL ER 20 MEQ TABLET K-SOL 20% (40 MEQ/15 ML) LIQ K-TAB ER 8 MEQ TABLET SALINE PREPARATION SODIUM CHLORIDE 0.45% SOLUTION NON URINARY PH MODIFIERS K-PHOS NEUTRAL TABLET PHOSPHA 250 NEUTRAL TABLET VIRT-PHOS 250 NEUTRAL TABLET VITAMINS & HEMATINICS COD LIVER OIL NON VITAMINS & HEMATINICS VITAMINS & HEMATINICS BETA-CAROTENE 25,000 UNITS CAP OTC BETA CAROTENE 10,000 UNITS CAP OTC BRAND OTC PREPARATIONS VITAMIN A VITAMIN B VITAMIN C VITAMIN D VITAMIN D COMBO VITAMIN E MISCELLANEOUS VITAMINS NON NON Page 2 of 8

VITAMINS & HEMATINICS GENERIC OTC PREPARATIONS VITAMIN A VITAMIN B VITAMIN C VITAMIN D VITAMIN D COMBO VITAMIN E MISCELLANEOUS VITAMINS EDITS NO CHANGES IN /NON STATUS REVISION OR ADDITION TO UM EDIT ONLY ACNE AND ROSACEA AGENTS MINOLIRA ADD ST ACNE AND ROSACEA AGENTS AKTIPAK ADD ST ACNE AND ROSACEA AGENTS ACNE THERAPY ALZHEIMER'S THERAPY; NMDA RECEPTOR ANTAGONISTS ANGIOTENSIN II RECEPTOR BLOCKERS & RENIN INHIBITOR ANGIOTENSIN RECEPTOR ANTAG. THIAZIDE DIURETIC COMB ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTICONVULSANTS ANTIEMETICS AND ANTIVERTIGO ANTIEMETICS AND ANTIVERTIGO ANTIHISTAMINES ANTIHISTAMINES ANTIMIGRAINE PREPARATIONS DIFFERIN GEL 0.1% GEL, OTC ADAPALENE 0.1% LOTION MEMANTINE HCL 10 MG TABLET TEKTURNA TABLETS TEKAMLO TABLETS DIOVAN HCT TABLETS APTIOM 200 MG & 400 MG APTIOM 600 MG & 800 MG GABAPENTIN SOLUTION LAMICTAL 100 MG ODT CINVANTI INFUSION VARUBI INJECTION CLARINEX 5 MG TABLET ALLEGRA ALLERGY 60 MG TABLET IMITREX 6 MG/0.5 ML VIAL (ML) 45 GMS PER QL REVISED 59 ML PER 30 S 72 ML PER 5 VIALS PER 30 S 2 VIALS PER 28 S QL REVISION 4 SYRINGES PER 30 S Page 3 of 8

ANTIPARASITICS ATYPICAL ANTIPSYCHOTIC ATYPICAL ANTIPSYCHOTIC ANTIPSYCHOTIC MISC CANCER CANCER CANCER CHOLINESTERASE INHIBITORS DECONGESTANT/ ANTIHISTAMINES DECONGESTANT/ ANTIHISTAMINES DIABETES ELECTROLYTE DEPLETERS EPINEPHRINE ERYTHROPOIESIS STIMULATING AGENTS SOLOSEC RISPERDAL 0.5 MG TABLET QUETIAPINE FUMARATE TABLETS SAPHRIS 5 MG TABLET OLANZAPINE 2.5 MG TABLET OLANZAPINE 5 MG TABLET OLANZAPINE 7.5 MG TABLET OLANZAPINE 15 MG TABLET OLANZAPINE 20 MG TABLET OLANZAPINE ODT 5 MG OLANZAPINE ODT 15 MG OLANZAPINE ODT 20 MG VYVANSE 70 MG CAPSULE COMETRIQ 80 MG VENCLEXTA STARTING PACK VERZENIO GALANTAMINE HBR TABLETS ALLEGRA-D OTC 60 MG-120 MG ER TABLET ALLEGRA-D OTC 180-240 MG ER TABLET BYDUREON BCISE RENVELA 800 MG TABLET SYMJEPI MIRCERA 30 MCG/0.3 ML 150 MCG/0.3 ML 2 G PER FILL; 1 FILL PER 30 S 1 CAPSULE PER 1 CAPSULE PER 1 PACK PER 365 S 4 AUTOINJECTORS PER 28 S 9 TABLETS PER 2 BOXES (2 PREFILLED SYRINGES) PER FILL 2 SYRINGES (0.6 ML) PER 28 S Page 4 of 8

ESTROGENS TRANSDERMAL ESTROGENS TRANSDERMAL EYE MAST CELL STABILIZERS FLUOROQUINOLONES GNRH ANALOG HIV ANTIRETROVIRALS HYPERAMMONEMIA HYPNOTIC AGENTS (NONINSULIN) HYPOGLYCEMIC AGENTS (NONINSULIN) HYPOGLYCEMIC AGENTS IDIOPATHIC PULMONARY FIBROSIS IDIOPATHIC PULMONARY FIBROSIS INHALED CORTICOSTEROIDS INHALED CORTICOSTEROIDS ESTRADIOL TDS PATCH ESTRADIOL PATCH MENOSTAR PATCH VIVELLE-DOT PATCH MINIVELLE PATCH CLIMARA PATCH ALORA PATCH MENOSTAR PATCH VIVELLE-DOT PATCH MINIVELLE PATCH CLIMARA PATCH ALORA PATCH CROMOLYN 4% EYE DROPS LEVAQUIN TABLETS TRIPTODUR ISENTRESS HD RAVICTI FLURAZEPAM HCL CAPSULES RESTORIL 7.5 MG CAPSULE RESTORIL 22.5 MG CAPSULE AMBIEN CR TABLETS ONGLYZA 2.5 MG TABLET JANUVIA TABLETS ACTOS TABLETS KOMBIGLYZE XR 5 MG-500 MG TABLET KOMBIGLYZE XR 5 MG-1000 MG TABLET AVANDIA TABLETS KOMBIGLYZE XR 2.5-1000 MG TABLET JANUMET TABLETS ESBRIET 267 MG TABLET ESBRIET 801 MG ALVESCO 80 MCG HFA ASMANEX INHALERS ALVESCO 160 MCG HFA REMOVE ST FOR T/F OF AN ORAL AGENT ADD ST FOR A TD ESTROGEN 10 ML (1 BOTTLE) PER 30 S 14 TABS PER FILL; 1 FILL PER 30 S 1 KIT EVERY 24 WEEKS ADD STEP THERAPY 1 TABLET/ CAPSULE PER 9 TABLETS PER 3 TABLETS PER 1 INH PER 30 S 2 INH PER 30 S Page 5 of 8

INHERITED DISORDERS OF METABOLISM INSULIN INSULIN INSULIN INTRANASAL STEROIDS INSULIN IRON REPLACEMENT LIPID/CHOLESTEROL LOWERING AGENTS MOVEMENT DISORDER MOVEMENT DISORDER BUPHENYL 250 GM POWDER AFREZZA 90 CARTRIDGES (12 UNIT) AFREZZA 180 CARTRIDGES (60X4 UNIT AND 60X8 UNIT AND 60X12 UNIT) FIASP, FIASP FLEXTOUCH BUDESONIDE 32 MCG AEROSOL, SPRAY WITH PUMP (ML) HUMALOG JUNIOR KWIKPEN FE C 100-250-1 TABLET CRESTOR TABLETS PRAVASTATIN SODIUM 10 MG TABLET PRAVACHOL TABLETS GOCOVRI ER 68.5 MG GOCOVRI ER 137 MG QL REVISED 750 GM PER 30 S 3 BOXES PER 30 S 2 BOXES PER 30 S 2 BOXES PER 30 S 2 INH PER 30 S 2 BOXES PER 30 S 1 PER 2 PER APAP/CAF/DIHYDROCODEINE 320.5/30/16 APAP/CAF/DIHYDROCODEINE 356.4/30/16 MG APAP/CAF/DIHYDROCODEINE 325/30/16 MG APAP/CODEINE 300/15 MG APAP/CODEINE 300/30 MG DIHYDROCODEINE/ASA/CAF 16/356/30 MG (SYNALGOS-DC) HYDROCODONE/APAP 10/500 MG, 7.5/500 MG HYDROCODONE/APAP 2.5/325 MG, 5/325 MG, 7.5/325 MG, 10/325 MG HYDROCODONE/APAP 5/300 MG, 7.5/300 MG, 10/300 MG HYDROCODONE/APAP 5/400 MG, 7.5/400 MG, 10/400 MG HYDROCODONE/APAP 5/500 MG TABLETS OXYCODONE 7.5/500 MG (PERCOCET) 6 CAPSULES OR OXYCODONE/APAP 10/500 MG TABLET TABLETS PER OXYCODONE/APAP 2.5/325 MG, 5/325 MG, 7.5/325 MG, 10/325 MG OXYCODONE/APAP 5/300 MG, 7.5/300 MG, 10/300 MG OXYCODONE/APAP 5/500 MG CAPSULE OXYCODONE/ASPIRIN 5/325 MG PENTAZOCINE/NALOXONE 50 MG/0.5 MG CODEINE SULFATE 15 MG CODEINE SULFATE 30 MG DILAUDID 2 MG DILAUDID 4 MG DEMEROL 50 MG MS IR 15 MG Page 6 of 8

OSTEOPOROSIS THERAPY OSTEOPOROSIS THERAPY OXYCODONE 10 MG OXAYDO 7.5 MG OXYIR 5 MG ROXICODONE 5 MG OXAYDO 5 MG OPANA 5 MG DOLOPHINE 5 MG APAP/CODEINE SUSP OR ELIXIR 120 MG-12 MG/5 ML; 300 MG-30 MG/12.5 ML (CAPITAL WITH CODEINE) HYDROCODONE/APAP 2.5-108 MG/5 ML SOLUTION HYDROCODONE/APAP 2.5-167 MG/5 ML SOLUTION OXYCODONE/APAP 5-325 MG/5 ML SOLUTION DEMEROL 50 MG/5 ML (ORAL) MORPHINE SULFATE SOLUTION 10 MG/5 ML MORPHINE SULFATE SOLUTION 20 MG/5 ML OXYCODONE SOLUTION 5 MG/5ML METHADONE SOLUTION 5 MG/5 ML HYDROCODONE/APAP 5-163 MG/7.5 ML HYDROCODONE/APAP 5-215 MG/10 ML HYDROCODONE/APAP 5-217 MG/10 ML SOLUTION HYDROCODONE/APAP 5-334 MG/10 ML MORPHINE SULFATE 20 MG/ML ORAL SYRINGE, 100 MG/5 ML SOLUTION NUCYNTA 50 MG HYSINGLA ER 80 MG, 100 MG EXALGO 12 MG, 16 MG, 32 MG ZOHYDRO ER 30 MG, 40 MG, 50 MG XTAMPZA ER 27 MG, 36 MG AVINZA 75 MG, 90 MG, 120 MG OXYCONTIN 60 MG, 80 MG OPANA ER 30 MG ALENDRONATE SODIUM 35 MG TABLET ACTONEL 35 MG TABLET ACTONEL 5 MG TABLET 30 ML PER 45 ML PER 60 ML PER 6 ML PER 181 PER 30 S 2 CAPSULES PER 1 CAPSULE PER 4 TABLETS PER 4 TABLETS PER 28 S Page 7 of 8

PROTON PUMP INHIBITORS SELECTIVE SEROTONIN REUPTAKE INHIBITORS SELECTIVE SEROTONIN REUPTAKE INHIBITORS SELECTIVE SEROTONIN REUPTAKE INHIBITORS SNRI SUBLINGUAL IMMUNTHERAPY TARGETED IMMUNE MODIFIERS DEXILANT 30 MG CAPSULE DR DEXILANT 60 MG CAPSULE DR LANSOPRAZOLE 30 MG CAP, DR EC PREVACID RX 30 MG TAB DISINTEGRATING DR ACIPHEX 20 MG TABLET EC CELEXA 20 MG FLUOXETINE HCL 20 MG PAROXETINE HCL 30 MG SERTRALINE HCL 100 MG VENLAFAXINE HCL IR TABS ODACTRA ENBREL MINI WITH AUTOTOUCH 1 PER 1.5 TABLETS PER 4 PER 2 TABS PER 3 TABLETS PER ADD PA AND QL 4 CARTRIDGES PER 28 S What action do I need to take? Please review these changes and work with your Amerigroup patients to transition them to formulary alternatives. If you determine preferred formulary alternatives are not clinically appropriate for specific patients, you will need to obtain prior authorization (PA) to continue coverage beyond the applicable effective date. What if I need assistance? We recognize the unique aspects of patients cases. If for medical reasons your Amerigroup patient cannot be converted to a formulary alternative, call our Pharmacy department at 1-800-454-3730 and follow the voice prompts for pharmacy PA. You can find the Preferred Drug List on our provider website at https://providers.amerigroup.com/ga. If you need assistance with any other item, contact your local Provider Relations representative or call Provider Services at 1-800-454-3730. Page 8 of 8